Navigation Links
SpectraScience Awarded Patent for Correcting Image Misalignment
Date:8/13/2008

SAN DIEGO, Aug. 13 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical devices company, today announced that it has been awarded a patent for correcting image misalignment between at least two images in a sequence of images due at least in part to tissue sample movement. The patent, U.S. Patent No. 7,406,215, is titled "Methods and systems for correcting image misalignment."

Jim Hitchin, SpectraScience's CEO, commented, "This is another key patent in our broad patent portfolio that furthers our commitment at SpectraScience to develop better, more reliable cancer screening technologies.

The patent is important to the Company's optical biopsy technology because, in screening for some forms of cancer, the optical response of the tissue is captured in a sequence of images that are characterized by analyzing the time-dependent response of the tissue as recorded in the sequence. During this type of screening, the tissue may move while images are being taken, resulting in a spatial shift within the image frame field. Being able to correct for this shift increases the effectiveness of the optical biopsy procedure. Tissue movement can be caused by the natural movement of the patient during the procedure, which can occur despite a patient's attempts to remain completely still. This patent provides for an accurate analysis of the sequence of images which would otherwise be misaligned due to movement of the tissue.

Hitchin added, Accurate imaging is critical to earlier and more effective identification of abnormal, pre-cancerous and/or cancerous tissue, and this invention provides methods of determining a correction for a misalignment in the imaging process that will make our screening devices more powerful to the physician and more important to the patient."

SpectraScience has filed for 60 patents worldwide on its WavSTAT(R) Optical Biopsy System and LUMA(R) Cervical Imaging System that are used to diagnose tissue to quickly determine if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are currently approved by the FDA for detecting pre-cancer and cancer in the colon and cervix, and an evaluation for detection of pre-cancers in the throat ("Barrett's esophagus") is being tested.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward- looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

Contact:

SpectraScience, Inc.

Jim Hitchin, Chief Executive Officer

(858) 847-0200 x201

Hayden Communications

Investor Relations

Todd Pitcher

(858)-518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Receives Final European Certification
2. SpectraScience Acquires Luma Imaging Corporation
3. SpectraScience, Inc. Retains Hayden Communications
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
6. SpectraScience Adds Industry Veteran to Executive Team
7. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
8. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
9. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
10. PartsSource Awarded US Patent for PartsFinder(TM) Application
11. Wrigleys Orbit(R), Extra(R) and Eclipse(R) Sugar-Free Chewing Gums Awarded American Dental Associations Seal of Acceptance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Michael Lanteri Agency ... created to assist the people of their local community. The agency pledges to ... community leaders. Their hope is to bring awareness to important local causes with ...
(Date:5/5/2016)... ... May 05, 2016 , ... A recent survey by the Midwest ... getting employees to understand and use the free preventive care benefits available to them ... business groups of large, self-insured public and private employers, MBGH found that only 10% ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... agency’s ongoing community enrichment program serving families of greater Dubuque, IA. The current ... duty, reserve and honorably discharged veterans. Donations to Veteran’s Freedom Center may now ...
(Date:5/5/2016)... ... May 05, 2016 , ... A local study examining ... than 40 percent of participating fifth-grade students already have or are at risk ... Clinical Research in the Division of Pulmonary, Allergy and Critical Care Medicine at ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... TIME for ... safety – today announced a new partnership to reach nearly 1 million children with ... in an instant and is the leading cause of accidental death in children one ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... CITY, Mo. , May 3, 2016 /PRNewswire/ ... Kansas Medical Center,s Institute for Advancing Medical Innovation ... and commercialize new drugs, diagnostics and medical devices. ... provides BioNovus Innovations with rights to license, develop ... "This partnership represents ...
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 ... and endovascular medical technology, today announced Food and ... a cardiac resynchronization defibrillator that provides heart failure ... (MRI) scans. Iperia devices also have remote monitoring ... (CLS) that adapts the heart rate in response ...
(Date:5/3/2016)... , May 3, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... by Field Strength (High Field, Very High Field, Low ... (Brain, Head and Neck, Spine, Musculoskeletal, Vascular, Breast, Pelvic ... global magnetic resonance imaging (MRI) market was valued at ...
Breaking Medicine Technology: